ADCT - ADC Therapeutics SA logo

ADC Therapeutics SA

ADCT

ADC Therapeutics SA develops antibody-drug conjugates to treat hematologic malignancies and solid tumors. Its main product, ZYNLONTA, targets relapsed lymphoma. The company is expanding its portfolio with multiple ADCs in various clinical trials.

โš•๏ธ Healthcare NYSE Listed 1979 $ USD
$1,000 invested 5 years ago โ†’$61today

Score Overview

1 Year
Score
Net Growth32.05%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-3.18%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score6.5
Net Growth57.87%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth132.23%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growthโ€”
Net Trend67%
Net Income Consistency
Rev Growthโ€”
Rev Trend56%
Revenue Consistency
All Time
Scoreโ€”
Net Growthโ€”
Net Trend67%
Net Income Consistency
Rev Growthโ€”
Rev Trend56%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where ADC Therapeutics SA has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ADCT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.60โ€”
1 Year2025-10-22
$ 4.07-60.69%
5 Years2021-10-22
$ 26.12-93.87%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 78M-$ 96M$ 219M
2025$ 81M-$ 142M$ 261M
2024$ 70M-$ 157M$ 250M
2023$ 69M-$ 240M$ 278M
2022$ 209M-$ 157M$ 326M
2021$ 33M-$ 230M$ 466M
2020$ 0.00-$ 246M$ 439M
2019$ 2M-$ 116M$ 115M
2018$ 1M-$ 123M$ 138M
2017$ 1M-$ 89M$ 262M
2016$ 143M
ADCT - ADC Therapeutics SA logo

ADC Therapeutics SA fundamental performance

Between 2020 and 2025, revenue grew from $ 0.00 to $ 81M and net income went from -$ 246M to -$ 142M. Revenue increased in 3 of those 5 years; net income in 4.

ADC Therapeutics SA currently holds a 5-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.

Membership

Explore ADCT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies